CO6870034A2 - Tratamiento de la menorragia asociada con fibromas uterinos - Google Patents

Tratamiento de la menorragia asociada con fibromas uterinos

Info

Publication number
CO6870034A2
CO6870034A2 CO14019457A CO14019457A CO6870034A2 CO 6870034 A2 CO6870034 A2 CO 6870034A2 CO 14019457 A CO14019457 A CO 14019457A CO 14019457 A CO14019457 A CO 14019457A CO 6870034 A2 CO6870034 A2 CO 6870034A2
Authority
CO
Colombia
Prior art keywords
treatment
uterine fibroids
menorrhagia
menorrhagia associated
fibroids
Prior art date
Application number
CO14019457A
Other languages
English (en)
Inventor
Ernest Loumaye
Elke Bestel
Ian Osterloh
Original Assignee
Preglem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6870034(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Preglem Sa filed Critical Preglem Sa
Publication of CO6870034A2 publication Critical patent/CO6870034A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO14019457A 2011-07-12 2014-01-30 Tratamiento de la menorragia asociada con fibromas uterinos CO6870034A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506704P 2011-07-12 2011-07-12
EP11173630A EP2545922A1 (en) 2011-07-12 2011-07-12 Treatment of excessive menstrual bleeding associated with uterine fibroids

Publications (1)

Publication Number Publication Date
CO6870034A2 true CO6870034A2 (es) 2014-02-20

Family

ID=44720552

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14019457A CO6870034A2 (es) 2011-07-12 2014-01-30 Tratamiento de la menorragia asociada con fibromas uterinos

Country Status (17)

Country Link
US (1) US9168264B2 (es)
EP (2) EP2545922A1 (es)
JP (1) JP2014520840A (es)
KR (1) KR101932789B1 (es)
CN (1) CN103648503A (es)
AU (1) AU2012282061B2 (es)
BR (1) BR112014000650A2 (es)
CA (1) CA2836346A1 (es)
CO (1) CO6870034A2 (es)
EA (1) EA026721B1 (es)
GE (1) GEP20166430B (es)
HU (1) HUE037294T2 (es)
IL (1) IL229515B (es)
MX (1) MX2014000474A (es)
MY (1) MY165571A (es)
WO (1) WO2013008202A1 (es)
ZA (1) ZA201400231B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
CA2905214A1 (en) * 2013-03-14 2014-09-18 Laboratoire Hra-Pharma Method for scheduling ovulation
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
JP6995757B2 (ja) 2015-12-23 2022-01-17 オリック ファーマシューティカルズ,インク. グルココルチコイド受容体の阻害剤
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP2019506443A (ja) * 2016-02-24 2019-03-07 イースタン バージニア メディカル スクール 改良された持効性注射用デポ型ブタン酸レボノルゲストレル懸濁製剤
EP3523315B1 (en) 2016-10-07 2021-03-24 Oric Pharmaceuticals, Inc. Inhibitor of glucocorticoid receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DK0806952T3 (da) * 1995-02-02 2003-06-16 Schering Ag Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
EP1613640A4 (en) 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
BRPI0513141A (pt) 2004-07-09 2008-04-29 Population Council Inc composição para anel vaginal, e, processo de contracepção a longo prazo
EP1874278B1 (en) * 2005-04-28 2009-06-24 Wyeth Compositions containing micronized tanaproget
AU2006294449A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
MX2009006912A (es) 2006-12-28 2009-08-12 Repros Therapeutics Inc Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas.
DK2148681T3 (en) * 2007-04-20 2016-07-04 Preglem Sa Selective progesteronmodulatorer in the treatment of uterine bleeding
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
ES2401555T3 (es) 2008-06-18 2013-04-22 Lexicon Pharmaceuticals, Inc. Formas sólidas de (1R,2S,3R)-1-(2-(isoxazol-3-il)-1H-imidazol-4-il)butano-1,2,3,4-tetraol y métodos de utilización de las mismas
DE202011110355U1 (de) * 2011-03-09 2014-01-15 Arstat, Inc. Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids

Also Published As

Publication number Publication date
US9168264B2 (en) 2015-10-27
EA201490209A1 (ru) 2014-06-30
GEP20166430B (en) 2016-02-10
EA026721B1 (ru) 2017-05-31
HUE037294T2 (hu) 2018-09-28
EP2545922A1 (en) 2013-01-16
NZ619478A (en) 2015-12-24
CA2836346A1 (en) 2013-01-17
CN103648503A (zh) 2014-03-19
EP2731613B1 (en) 2017-08-30
MY165571A (en) 2018-04-05
IL229515B (en) 2018-01-31
AU2012282061A1 (en) 2014-01-23
JP2014520840A (ja) 2014-08-25
BR112014000650A2 (pt) 2020-10-27
WO2013008202A1 (en) 2013-01-17
IL229515A0 (en) 2014-01-30
MX2014000474A (es) 2014-02-20
AU2012282061B2 (en) 2016-11-10
EP2731613A1 (en) 2014-05-21
KR20140050614A (ko) 2014-04-29
ZA201400231B (en) 2014-10-29
KR101932789B1 (ko) 2018-12-27
US20140148419A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
HK1212388A1 (en) Methods of tissue generation
HK1212261A1 (en) Methods of tissue generation
CO6930321A2 (es) Curación de tejidos
CO6960555A2 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CO6960513A2 (es) Ancla quirúrgica
PT2886065T (pt) Acionador aperfeiçoado para instrumento cirúrgico
DK2591099T3 (da) Kimære koagulationsfaktorer
BR112014025085A2 (pt) Conexão elétrica giratória para instrumentos cirúrgicos ultrassônicos
CO6870034A2 (es) Tratamiento de la menorragia asociada con fibromas uterinos
DK3011936T3 (da) Vævsmanipulerede konstrukter
BR112013024527A2 (pt) pessário
DE102011075781A8 (de) Elektrochirurgisches Instrument
DK2568889T3 (da) Kirurgisk instrument
DK2640598T3 (da) Strækningsisolator
BR112014003660A2 (pt) suporte de trocarte
BRDI7104779S (pt) Configuração aplicada em instrumento médico
DK3141227T3 (da) Kirurgisk øjenanordning
BR302012003224S1 (pt) Configuração aplicada em instrumento médico
BR112014004618A2 (pt) aparelho de sutura cirúrgico
BR112013011858A2 (pt) métodos para reforçar oxigenação de tecido comprometido
FR2997292B1 (fr) Plaque de translation du calcaneum
BR112014015097A8 (pt) aperfeiçoada etapa de pré-hidrólise envolvendo vácuo
FR2987600B1 (fr) Nacelle aplatie de turboreacteur
IT1400937B1 (it) Procedimento per ottenere propoli anallergica
ES1077912Y (es) Simulador de sutura uterina

Legal Events

Date Code Title Description
FC Application refused